Global Information would like to present a new market research report, "Renal Cell Carcinoma Drug Discoveries: what the future holds" by Espicom Business Intelligence.
The RCC market has recently attracted significant investments in research and development from big pharma, specialty pharma, and biotechnology companies. Historically, the market for RCC treatments has comprised a comparatively small section of the oncology market. The RCC market has evolved into a rapidly growing segment since the launch of newer targeted therapies, such as: Pfizers Sutent (sunitinib), Roches Avastin (bevacizumab), Pfizers Torizel (temsirolimus), and Bayer/Onyx Nexavar (sorafenib). In monetary terms, almost $2.2 billion was spent on branded drugs for RCC treatment in the year 2008.
Research and analysis shows that the number of RCC patients by value in the US, the top five countries in Europe, and Japan will rise to 35.7% by the year 2015. More specifically, the number of patients in 2008 totaled around 613,000 and will increase to about 832,000 by 2015. Espicom Business Intelligence estimates that around 18% of renal cell carcinoma patients currently receive drug therapy. It is expected that a higher percentage of patients will receive RCC treatments by 2015, which indicates growth in the number of treatment options, drug efficacy improvements, and earlier drug therapy use in the course of the disease.